{"id":8662,"date":"2020-06-01T09:02:15","date_gmt":"2020-06-01T08:02:15","guid":{"rendered":"https:\/\/www.hgf.com\/?p=8662"},"modified":"2026-02-17T16:16:52","modified_gmt":"2026-02-17T16:16:52","slug":"covid-19-licensing-challenges","status":"publish","type":"post","link":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/","title":{"rendered":"COVID-19 licensing challenges"},"content":{"rendered":"<div class=\"intro text-content-container\">\n<p class=\"p__large\">The taking of new therapies and technologies forward to meet the challenges of COVID-19 is happening at previously unprecedented rates. MHRA is taking flexible approaches to regulation during the COVID-19 outbreak. [1] This includes providing expedited scientific advice, and rapid reviews of clinical trials applications.<\/p>\n<\/div>\n<p>The speed of progress means that it is challenging for you to know:<\/p>\n<ul>\n<li>that you have freedom to operate (FTO) i.e. you will not infringe anyone else\u2019s therapy or technology, and do not need a licence; and<\/li>\n<li>on what terms to license in necessary technologies and license out your own technology, when the focus is on just getting help to patients now.<\/li>\n<\/ul>\n<p>Whilst you should still look at your FTO position, there are some exemptions and non-assert\/licensing arrangements that might help you out in the short-term.<\/p>\n<h5>Infringement exemptions<\/h5>\n<p>At the pure research stage, you may not need a patent licence. Can you rely on the experimental use exemption? [2] In other words is what you are doing for experimental purposes relating to the subject-matter of the patented invention. This exemption does not extend to testing\/clinical trials.[3]<\/p>\n<p>An additional exemption was introduced for activities conducted only to obtain an abridged marketing authorisation application.[4] This is often known as the Bolar exemption. There is now also an exemption for anything done in or for the purposes of a medicinal product assessment.[5]\u00a0This includes any testing, course of testing or other activity undertaken with a view to providing data for\u00a0obtaining or varying an authorisation to sell or supply, or offer to sell or supply, a medicinal product anywhere.[6] Both of these exemptions only apply to medicinal products and not to medical devices.<\/p>\n<h5>Non-assert agreements\/licences<\/h5>\n<p>So, what happens when you want to commercialise? You might be protected against infringement under an Open COVID Pledge. Various organisations, including Microsoft, Intel and Mitsubishi Electric, have made the following pledge:<\/p>\n<p><strong>\u2026 to make our intellectual property available free of charge for use in ending the COVID-19 pandemic and minimizing the impact of the disease<\/strong>.[7]<\/p>\n<p>They will do this through a licence specifying the full terms. That licence will last until one year after the World Health Organization (WHO) declares the COVID-19 pandemic to have ended or 1 January 2023.<\/p>\n<p>Over 80 Japanese organisations, including Canon, Kyoto University\u2019s Center for Genomic Medicine, Nissan and Toyota, have their own Open COVID Declaration. They have agreed not to enforce their patents and copyrights\u00a0<em>during the time of this crisis<\/em>, against any activities whose\u00a0sole purpose is stopping the spread of COVID-19, including diagnosis, prevention, containment and treatment.[8]<\/p>\n<p>The pledge companies are mainly in the electronics\/IT sector. So, what if there is no pledge which can help you? There are many organisations committing to deal with licences quickly.<\/p>\n<p>Several US universities, including Stanford, Harvard and MIT, have signed up to the COVID-19 Technology Access Framework.[9] Under this they commit to implementing COVID-19 patenting and licensing strategies to facilitate rapid global access. For most types of technologies, this includes the use of\u00a0<strong>rapidly executable non-exclusive royalty-free licenses<\/strong>\u00a0to IP they can license,\u00a0<strong>for the purpose of making and distributing products to prevent, diagnose and treat COVID-19 infection during the pandemic and for a short period thereafter.<\/strong>\u00a0In return for these royalty-free licences, licensees are asked to commit to distribute the resulting products as widely as possible and at a low cost that allows broad accessibility during the term of the licence.<\/p>\n<p>AUTM (the US Association of University Technology Managers), of which some UK universities are members, has issued COVID-19 Licensing Guidelines to facilitate a rapid pandemic response. It says it is best accomplished by adopting\u00a0<strong>time-limited, non-exclusive royalty-free licenses<\/strong>, in exchange for the\u00a0<strong>licensees\u2019 commitment to rapidly make and broadly distribute products and services to prevent, diagnose, treat and contain COVID-19 and protect healthcare workers during the pandemic<\/strong>. Those licences may subsequently convert to more typical commercial licences.<\/p>\n<p>As the pandemic continues most organisations, however, even if they are not signed up to a pledge or guidelines, are keen to get licences agreed rapidly. The concepts contained in the pledges and the guidelines are useful in giving guidance as to the type of licences that might be on offer. They may also guide the type of licences which you might grant.<\/p>\n<p>Many organisations are looking to license on a non-exclusive basis. That licence may be free-of-charge or at reduced rates for a limited period. For instance, that period could be until the WHO declares the COVID-19 pandemic has ended or for 12 months or for longer periods, such as under the Open COVID Pledge. After that licences would be on normal commercial terms. If those terms have not been agreed up-front, you should aim to be discussing them well ahead of the expiry of the free-of-charge or reduced rates.<\/p>\n<p>Finding licensing partners is not always easy. UCL has a non-commercial site, Covid-19 Licensing, dedicated to distributing technologies related to the fight against\u00a0COVID-19.[10] It is using it to license the UCL-Ventura breathing aid,\u00a0developed by UCL and the Mercedes-AMG F1 team for use by the UK\u2019s NHS. UCLB offers free hosting and licensing of IP submitted by university TTOs where the IP is fully developed and ready to be licensed. Those licences can be time-limited but must be free of charge.<\/p>\n<h5>Conclusion<\/h5>\n<p>The world is moving rapidly to beat COVID-19. It is good to know that, if you infringe someone else\u2019s IP, in the short-term in relation to COVID-19 there are often ways to address it. We find that most organisations are happy to be accommodating on sensible terms. If you have technology to license yourself, the key is to move quickly to complete your deals. In our experience a well-crafted Term Sheet will help achieve this. Time will tell whether all licences entered into today can be extended beyond the pandemic period.<\/p>\n<div>\n<div>\n<p>[1]\u00a0<a href=\"https:\/\/www.gov.uk\/guidance\/mhra-regulatory-flexibilities-resulting-from-coronavirus-covid-19\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.gov.uk\/guidance\/mhra-regulatory-flexibilities-resulting-from-coronavirus-covid-19<\/a><\/p>\n<p>[2] s.60(5)(b) Patents Act 1977<\/p>\n<p>[3]\u00a0<em>Monsanto Co v Stauffer Chemical Co\u00a0(1985) RPC 515, Auchincloss and Another v Agricultural and Veterinary Supplies and Others<\/em>\u00a0[1999] RPC 397 and\u00a0<em>CoreValve v Edwards Lifesciences<\/em>\u00a0[2009] FSR 8<\/p>\n<p>[4] s.60(5)(i) Patents Act 1977<\/p>\n<p>[5] s.60(6D) Patents Act 1977<\/p>\n<p>[6] s.60(6E) Patents Act 1977<\/p>\n<p>[7]\u00a0<a href=\"https:\/\/opencovidpledge.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/opencovidpledge.org\/<\/a><\/p>\n<p>[8]\u00a0<a href=\"https:\/\/www.gckyoto.com\/covid-2\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.gckyoto.com\/covid-2<\/a><\/p>\n<p>[9]\u00a0<a href=\"https:\/\/autm.net\/about-tech-transfer\/covid19\/covid-19-licensing-guidelines\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/autm.net\/about-tech-transfer\/covid19\/covid-19-licensing-guidelines<\/a><\/p>\n<p>[10] <a href=\"https:\/\/covid19.e-lucid.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/covid19.e-lucid.com\/<\/a><\/p>\n<p class=\"p__medium\">This article was prepared by HGF Partner\u00a0<a href=\"\/our-people\/janet-knowles\/\">Janet Knowles<\/a>.\u00a0If you would like further advice on this or any other matter, please contact Janet. Alternatively, you can contact your usual HGF representative or visit our\u00a0<a href=\"\/contact\/\">Contact page<\/a>\u00a0to get in touch with your nearest HGF office.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The taking of new therapies and technologies forward to meet the challenges of COVID-19 is happening at previously unprecedented rates. MHRA is taking flexible approaches to regulation during the COVID-19 &hellip;<\/p>\n","protected":false},"author":315,"featured_media":9004111222127492,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[497,509],"tags":[],"class_list":["post-8662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-knowledge-hub","category-legal-updates","sector-healthcare","sector-pharmaceuticals","service-patents","sector_groups-law"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.7 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>COVID-19 licensing challenges - HGF<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19 licensing challenges\" \/>\n<meta property=\"og:description\" content=\"The taking of new therapies and technologies forward to meet the challenges of COVID-19 is happening at previously unprecedented rates. MHRA is taking\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/\" \/>\n<meta property=\"og:site_name\" content=\"HGF\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-01T08:02:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-17T16:16:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/02\/hgf-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Akvil\u0117 Lukauskaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@behrooz@tall.agency\" \/>\n<meta name=\"twitter:site\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Akvil\u0117 Lukauskaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/\"},\"author\":{\"name\":\"Akvil\u0117 Lukauskaite\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/e6343663c5ee3e1ccea20cd220f97f30\"},\"headline\":\"COVID-19 licensing challenges\",\"datePublished\":\"2020-06-01T08:02:15+00:00\",\"dateModified\":\"2026-02-17T16:16:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/\"},\"wordCount\":1083,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/hgf-logo.jpg\",\"articleSection\":[\"Knowledge Hub\",\"Legal Updates\"],\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/\",\"name\":\"COVID-19 licensing challenges - HGF\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/hgf-logo.jpg\",\"datePublished\":\"2020-06-01T08:02:15+00:00\",\"dateModified\":\"2026-02-17T16:16:52+00:00\",\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/legal-updates\\\/covid-19-licensing-challenges\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/hgf-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/hgf-logo.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"name\":\"HGF\",\"description\":\"Intellectual Property Rights specialists\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\",\"name\":\"HGF\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"width\":696,\"height\":696,\"caption\":\"HGF\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hgf_ip\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hgf-limited-intellectual-property-specialists\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/e6343663c5ee3e1ccea20cd220f97f30\",\"name\":\"Akvil\u0117 Lukauskaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g\",\"caption\":\"Akvil\u0117 Lukauskaite\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/behrooz@tall.agency\",\"Behrooz Saeed\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"COVID-19 licensing challenges - HGF","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/","og_locale":"de_DE","og_type":"article","og_title":"COVID-19 licensing challenges","og_description":"The taking of new therapies and technologies forward to meet the challenges of COVID-19 is happening at previously unprecedented rates. MHRA is taking","og_url":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/","og_site_name":"HGF","article_published_time":"2020-06-01T08:02:15+00:00","article_modified_time":"2026-02-17T16:16:52+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/02\/hgf-logo.jpg","type":"image\/jpeg"}],"author":"Akvil\u0117 Lukauskaite","twitter_card":"summary_large_image","twitter_creator":"@behrooz@tall.agency","twitter_site":"@hgf_ip","twitter_misc":{"Verfasst von":"Akvil\u0117 Lukauskaite","Gesch\u00e4tzte Lesezeit":"5 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/#article","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/"},"author":{"name":"Akvil\u0117 Lukauskaite","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/e6343663c5ee3e1ccea20cd220f97f30"},"headline":"COVID-19 licensing challenges","datePublished":"2020-06-01T08:02:15+00:00","dateModified":"2026-02-17T16:16:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/"},"wordCount":1083,"commentCount":0,"publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"image":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/02\/hgf-logo.jpg","articleSection":["Knowledge Hub","Legal Updates"],"inLanguage":"de-DE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/","url":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/","name":"COVID-19 licensing challenges - HGF","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/#primaryimage"},"image":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/02\/hgf-logo.jpg","datePublished":"2020-06-01T08:02:15+00:00","dateModified":"2026-02-17T16:16:52+00:00","inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/legal-updates\/covid-19-licensing-challenges\/#primaryimage","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/02\/hgf-logo.jpg","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/02\/hgf-logo.jpg","width":1920,"height":1080},{"@type":"WebSite","@id":"https:\/\/www.hgf.com\/de\/#website","url":"https:\/\/www.hgf.com\/de\/","name":"HGF","description":"Intellectual Property Rights specialists","publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hgf.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.hgf.com\/de\/#organization","name":"HGF","url":"https:\/\/www.hgf.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","width":696,"height":696,"caption":"HGF"},"image":{"@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hgf_ip","https:\/\/www.linkedin.com\/company\/hgf-limited-intellectual-property-specialists\/"]},{"@type":"Person","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/e6343663c5ee3e1ccea20cd220f97f30","name":"Akvil\u0117 Lukauskaite","image":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/secure.gravatar.com\/avatar\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9cf1622c8c99b4c7573ba733a04f6352d3557803ca19afd3e4aafc94d9bc0b8?s=96&d=mm&r=g","caption":"Akvil\u0117 Lukauskaite"},"sameAs":["https:\/\/x.com\/behrooz@tall.agency","Behrooz Saeed"]}]}},"_links":{"self":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/8662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/users\/315"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/comments?post=8662"}],"version-history":[{"count":0,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/8662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media\/9004111222127492"}],"wp:attachment":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media?parent=8662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/categories?post=8662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/tags?post=8662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}